New pneumococcal vaccine welcomed by Meningitis UK
19.01.10
MENINGITIS UK has welcomed the Department of Health's announcement that a new vaccine to combat pneumococcal disease will be introduced in the spring.
The Prevenar 13 vaccine, manufactured by Wyeth Pharmaceuticals, now protects against 13 strains of the disease, compared to the previous vaccine which covered seven.
Steve Dayman, the Chief Executive of Meningitis UK who lost his own son to meningitis, said: "This is another landmark on the road to eradicating meningitis.
"Today's announcement will bring much comfort to the charity's supporters nationwide, many of whom have experienced the devastation that meningitis has caused."
The new vaccine will follow exactly the same three dose schedule that is used at present: one vaccination at two, four and 13 months old.
Public Health Minister Gillian Merron said: "From this spring, this vaccine will provide greater protection to children and marks yet another improvement this government has made to our world class Childhood Immunisation Programme.
"I am proud that we have been so successful in protecting children against serious diseases and that we have drastically reduced instances of illnesses and death."
Pneumococcal meningitis is the second most common form of bacterial meningitis in the UK.
Although pneumococcal meningitis is less common than meningococcal meningitis, it is a lot more life-threatening.
One in six children who contract pneumococcal meningitis will die and half of those who survive will be left with severe disabilities such as deafness, brain damage and seizures.
While the new vaccine will protect against the majority of disease-causing strains, it remains important to be vigilant and know the symptoms.
Young children, older people and those with weakened immune systems are at higher risk of contracting pneumococcal disease.





Comments
Posts: 3
Reply #3 on : Thu October 14, 2010, 07:57:28
Posts: 3
Reply #2 on : Wed January 20, 2010, 17:25:47
Posts: 3
Reply #1 on : Wed January 20, 2010, 17:00:41
Comments are temporarily closed for this article